- Acipimox
- Acipimox
- 000-00-0nondairy creamer
- 0000-0-01-(4-methylphenyl)-1-(2-pyridyl)-3-pyrrolidinopropan-1-ol
- 000000-00-0N-Cbz-exo-3-aminotropane
- 000050-32-8Benzo(a)pyrene
- 000051-03-6Piperonyl butoxide
- 000051-21-8Fluorouracil (5-Fluorouracil)
- 000052-51-72-Bromo-2-nitropropane-1,3-diol (Bronopol)
- 000052-85-7Famphur
- 000053-70-3Dibenzo(a,h)anthracene
- 000055-38-9Fenthion (O,O-Dimethyl O-[3-methyl-4-(methylthio) phenyl] ester, phosphorothioic acid)
Hot Products
|
Basic Information |
|
Post buying leads |
|
Suppliers |
| Name |
Acipimox |
EINECS | N/A |
| CAS No. | Density | N/A | |
| PSA | N/A | LogP | N/A |
| Solubility | N/A | Melting Point |
N/A |
| Formula | N/A | Boiling Point | N/A |
| Molecular Weight | N/A | Flash Point | N/A |
| Transport Information | N/A | Appearance | N/A |
| Safety | Risk Codes | N/A | |
| Molecular Structure |
|
Hazard Symbols | N/A |
| Synonyms |
N/A |
Acipimox Chemical Properties
IUPAC Name: 5-Methyl-4-oxido-pyrazin-4-ium-2-carboxylic acid
Synonyms: 2-Pyrazinecarboxylic acid, 5-methyl-, 4-oxide ; 5-Methylpyrazine-2-carboxylic acid 4-oxide ; 2-Carboxy-5-methylpyrazine 4-Oxide ; 5-Methyl-2-pyrazinecarboxylic acid 4-oxide
Product Categories: Pyrazine
Molecular Structure of Acipimox (CAS NO.51037-30-0) : 
Molecular Formula of Acipimox (CAS NO.51037-30-0) : C6H6N2O3
Molecular Weight of Acipimox (CAS NO.51037-30-0) : 154.12
CAS NO: 51037-30-0
EINECS : 256-928-3
Index of Refraction: 1.608
Surface Tension: 57.4 dyne/cm
Density: 1.44 g/cm3
Flash Point: 279.8 °C
Enthalpy of Vaporization: 85.92 kJ/mol
Boiling Point: 539 °C at 760 mmHg
Vapour Pressure: 1.88E-12 mmHg at 25°C
Melting Point: 177-180 °C
Storage temp: 2-8°C
Acipimox Uses
Acipimox (CAS NO.51037-30-0) is a niacin derivative used as a hypolipidemic agent. It is used in low doses and may have less marked adverse effects,although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid . These drug inhibit hepatic triglyceride production and VLDL secretions,which leads indirectly to a modest reduction in LDL and increase in HDL. Longterm administration is associated with reduced mortality, but unwanted effects limit it's clinical use. Adverse effects include flushing ( associated with Prostaglandin D2 ), palpitations, and GIT distrubances. Flushing can be reduced by taking aspirin 20-30 min before. High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout.
Acipimox Production
Raw materials: Chloroform-->Hydrogen peroxide-->Maleic anhydride -->5-Methyl-2-pyrazinecarboxylic acid
With cooling and stirring, adding 78g Maleic anhydride in 60ml chloroform solution,dissolved , adding 40ml 30% hydrogen peroxide. 2h later, adding 4.8g 5 - Methylpyrazine-2-carboxylic acid, at 0-5 °C, remain 2d. Filtered Maleic acid. Concentrated to a small residual volume, adding Ethyl acetate, filteried, obtaining 1.1g Acipimox.
Acipimox Safety Profile
Hazard Codes 
Xi
Risk Statements 36
R36:Irritating to eyes.
Safety Statements 26
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
RTECS UQ2453000